Phase 3, open label, randomized, comparative study of ticilimumab and either dacarbazine or temozolomide in patients with advanced melanoma

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-002827-15

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To compare overall survival for patients with advanced melanoma who are randomized toreceive ticilimumab with that of patients who are randomized to receive eitherdacarbazine or temozolomide.


Critère d'inclusion

  • Advanced Melanoma